十一酸雌二醇
參考

1 2 3 4  Zink C. . Walter de Gruyter. 1 January 1988: 85. ISBN 978-3-11-085727-6.
1 2  Stanczyk FZ, Archer DF, Bhavnani BR. . Contraception. June 2013, 87 (6): 706–727. PMID 23375353. doi:10.1016/j.contraception.2012.12.011.
↑  Emmens CW. . Elsevier Science. 22 October 2013: 394–. ISBN 978-1-4832-7286-3.
1 2 3 4  Kuhl H. . Climacteric. August 2005, 8 (Suppl 1): 3–63. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875.
↑  Falcone T, Hurd WW. . Elsevier Health Sciences. 2007: 22,362,388  [2024-01-18]. ISBN 978-0-323-03309-1. （原始内容存档于2023-01-10）.
1 2 3 4  Oettel M, Schillinger E. . Springer Science & Business Media. 6 December 2012: 261,544. ISBN 978-3-642-60107-1. Natural estrogens considered here include: [...] Esters of 17β-estradiol, such as estradiol valerate, estradiol benzoate and estradiol cypionate. Esterification aims at either better absorption after oral administration or a sustained release from the depot after intramuscular administration. During absorption, the esters are cleaved by endogenous esterases and the pharmacologically active 17β-estradiol is released; therefore, the esters are considered as natural estrogens.
1 2
1 2 3
1 2 3 4
↑  Elks J. . Springer. 14 November 2014: 898–. ISBN 978-1-4757-2085-3.
↑  Roberts AD. . CRC Press. 1991: 415  [20 May 2012]. ISBN 978-0-412-27060-4.
1 2 3  . Taylor & Francis US. 2000: 405  [20 May 2012]. ISBN 978-3-88763-075-1.
1 2 3 4 5  Norman G, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK,  et al. . British Journal of Cancer. February 2008, 98 (4): 697–707. PMC 2259178 . PMID 18268497. doi:10.1038/sj.bjc.6604230.
1 2 3  Schlatterer K, von Werder K, Stalla GK. . Experimental and Clinical Endocrinology & Diabetes. 1996, 104 (6): 413–419. PMID 9021341. S2CID 25099676. doi:10.1055/s-0029-1211479.
1 2 3  Benjamin H, Lal GB, Green R, Masters RE. . Ace Publishing Company. 1966: 107. Another preparation of even higher potency is Squibb's Delestrec, which at this writing is not yet on the market in the United States, but is well known in Germany and other European countries under the name of Progynon Depot (Schering). It is chemically Estradiol Undecylate in oil, likewise slowly absorbing, and containing 100 mg. to 1 cc. Injections of 1 cc. once or twice a month can be sufficient. Occasionally, however, larger doses are required to influence the patient's emotional distress.
1 2 3  Israel GE. . Temple University Press. March 2001: 64–. ISBN 978-1-56639-852-7.
↑  .   [2024-01-18]. （原始内容存档于2018-06-18）.
1 2 3 4 5 6 7 8 9 10  Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R. . British Journal of Urology. June 1980, 52 (3): 208–215. PMID 7000222. doi:10.1111/j.1464-410x.1980.tb02961.x.
↑
↑  Lembeck F, Sewing KF. . Springer-Verlag. 7 March 2013: 113–. ISBN 978-3-642-65621-7.
↑
↑
↑
↑
↑
↑  Mutschler E, Derendorf H. . CRC Press. 1995: 609  [30 January 2013]. ISBN 978-0-8493-7774-7.
↑  Enfedjieff M.  [Experiences with hormonal treatment of prostatic carcinoma]. Zeitschrift für Urologie und Nephrologie. March 1974, 67 (3): 171–173. PMID 4848715. （原始内容存档于2018-11-23） （德语）. Treatment of prostatic carcinoma in 256 patients using parenteral injections of Progynon Depot (a depto estradiol preparation) is reproted. 58% of patients survived 3 or more years from beginning of treatment, and in 70% therapeutic results were considered good with regression of tumor mass, reduction or disappearance of pain, normalization of miction, and improved general status. Results of estrogen treatment are evident within 3 months in most cases. Side effects include gynecomastia in 95% of cases, impotence in almost all patients, and atrophic changes in the testicles, which may actually be desirable. Prostatectomy is not recommended because of the high incidence of metastases even when prostatic disease is still small, because of the high operative mortality, and because of the undesirable after-effects. Orchidectomy was performed in patients in whom the prostatic capsule had been invaded, or who had distant metastases. Estrogen therapy for prostatic carcinoma gives excellent results, and is very easy for both patient and physician.
1 2 3 4  Tunn UW.  [Antiandrogens in the Treatment of Advanced Prostate Cancer].  [Conservative Therapy of Prostate Cancer]. 1987: 113–121. ISBN 978-3-540-17724-1. doi:10.1007/978-3-642-72613-2_12 （德语）.
↑  Saborowski KJ,  [Conservative Therapy with Cyproterone Acetate and Estradiol Undecylate in Advanced Prostate Cancer: A 5-Year Study], Bochum, Univ., Diss., 1988, OCLC 917571781, OL 24895092W （德语）
↑  Mollard P.  [Clinical action of estradiol undecylate in the treatment of prostatic cancer]. Lyon Medical. March 1963, 209: 759–765. PMID 13935867 （法语）.
↑  Schubert GE, Ziegler H, Völter D.  [Comparison of histological and cytological studies of the prostate with special reference to oestrogene induced changes]. Verhandlungen der Deutschen Gesellschaft für Pathologie. 1973, 57: 315–318  [2018-11-23]. PMID 4142204. （原始内容存档于2018-11-23） （德语）.
↑  Satoskar RS, Bhandarkar SD, Rege NN. . Popular Prakashan. 1973: 934–. ISBN 978-81-7991-527-1.
1 2  Morgan HG, Morgan MH. . Churchill Livingstone. 1984: 75. ISBN 978-0-443-02613-3. Treatment of sexual offenders. Hormone therapy. [...] Oestrogens may cause breast hypertrophy, testicular atrophy, osteoporosis (oral ethinyl oestradiol 0.01-0.05 mg/day causes least nausea). Depot preparation: oestradiol [undecyleate] 50-100mg once every 3–4 weeks. Benperidol or butyrophenone and the antiandrogen cyproterone acetate also used.  含有內容需登入查看的頁面 (link)
↑  Kennedy BJ. . Cancer Chemother Rep. April 1967, 51 (2): 491–495.
↑
↑
↑
↑  Kleemann A, Engel J, Kutscher B, Reichert D.  5th. Thieme. 2009: 1167–1174. ISBN 978-3-13-179525-0.
↑
↑
↑  Lauritzen C, Studd JW. . CRC Press. 22 June 2005: 95–98,488. ISBN 978-0-203-48612-2.
↑  Laurtizen C.  (PDF). Fisch FH  (编). . Krause & Pachernegg: Gablitz. 2001: 67–88  [2024-01-18]. ISBN 978-3-901299-34-6. （原始内容存档 (PDF)于2018-05-10）.
↑  Midwinter A. . Campbell S  (编). . MTP Press Limited. 1976: 377–382. ISBN 978-94-011-6167-1. doi:10.1007/978-94-011-6165-7_33.
1 2  Jacobi GH. . Schröder FH  (编). . Schering Nederland BV. June 1982: 161–169. ISBN 978-9090004327. OCLC 11786945.
↑  Tunn UW, Graff J, Senge T. . Schröder FH  (编). . Schering Nederland BV. June 1982: 149–159. ISBN 978-9090004327. OCLC 11786945.
1 2  Tunn UW, Radlmaier A, Neumann F. . Stoll BA  (编). . 1988: 43–56. ISBN 978-3-8055-4686-7. doi:10.1159/000415355.
1 2  Schröder FH, Radlmaier A. . Jordan VC, Furr BJ  (编). . Cancer Drug Discovery and Development. Humana Press. 2009: 325–346. ISBN 978-1-60761-471-5. doi:10.1007/978-1-59259-152-7_15.
1 2 3  Ackermann R, Altwein JE, Faul P. . Springer-Verlag. 13 March 2013: 276–277. ISBN 978-3-642-84264-1.
↑  Namer M. . Journal of Steroid Biochemistry. October 1988, 31 (4B): 719–729. PMID 2462132. doi:10.1016/0022-4731(88)90023-4.
↑  Jacobi GR, Tunn UW, Senge TH. . Jacobi GH, Hohenfellner R  (编). . Williams & Wilkins. 1 December 1982: 305–319. ISBN 978-0-683-04354-9.
↑  Altwein JE, Jacobi GH, Hohenfellner R. . . 1978.
1 2 3 4 5  Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY,  et al. . Pulmonary Circulation. 1983, 10 (1): 40–48. PMC 7052475 . PMID 32166015. S2CID 23447326. doi:10.1007/BF00326861.
↑  Jacobi GH, Wenderoth UK. . European Urology. 1982, 8 (3): 129–134. PMID 6281023. doi:10.1159/000473499.
↑  Ockrim J, Lalani EN, Abel P. . Nature Clinical Practice. Oncology. October 2006, 3 (10): 552–563. PMID 17019433. S2CID 6847203. doi:10.1038/ncponc0602.
↑  Lycette JL, Bland LB, Garzotto M, Beer TM. . Clinical Genitourinary Cancer. December 2006, 5 (3): 198–205. PMID 17239273. doi:10.3816/CGC.2006.n.037.
↑  Russell N, Cheung A, Grossmann M. . Endocrine-Related Cancer. August 2017, 24 (8): R297–R313. PMID 28667081. doi:10.1530/ERC-17-0153 .
↑  Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC,  et al. . The Lancet. Oncology. April 2013, 14 (4): 306–316. PMC 3620898 . PMID 23465742. doi:10.1016/S1470-2045(13)70025-1.
↑  Langley RE, Gilbert DC, Duong T, Clarke NW, Nankivell M, Rosen SD,  et al.  (PDF). Lancet. February 2021, 397 (10274): 581–591  [2024-01-18]. PMC 7614681 . PMID 33581820. S2CID 231885186. doi:10.1016/S0140-6736(21)00100-8. （原始内容存档 (PDF)于2024-01-18）.
↑
↑
↑  Asscheman H, Gooren LJ, Assies J, Smits JP, de Slegte R. . Clinical Endocrinology. June 1988, 28 (6): 583–588. PMID 2978262. S2CID 29214187. doi:10.1111/j.1365-2265.1988.tb03849.x.
↑  Asscheman H, Gooren LJ, Eklund PL. . Metabolism. September 1989, 38 (9): 869–873. PMID 2528051. doi:10.1016/0026-0495(89)90233-3.
↑  Gazzeri R, Galarza M, Gazzeri G. . The New England Journal of Medicine. December 2007, 357 (23): 2411–2412. PMID 18057351. doi:10.1056/NEJMc071938 .
↑
1 2  Lauritzen C. . Maturitas. September 1990, 12 (3): 199–214. PMID 2215269. doi:10.1016/0378-5122(90)90004-P.
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5 6
1 2 3
↑
↑  von Bruchhausen F, Dannhardt G, Ebel S, Frahm AW, Hackenthal E, Holzgrabe U. . Springer-Verlag. 2 July 2013: 84–. ISBN 978-3-642-57994-3.
1 2
↑  . CRC Press. 2004: 469–. ISBN 978-3-88763-101-7.
↑  Boschann HW. . Annals of the New York Academy of Sciences. July 1958, 71 (5): 727–752. Bibcode:1958NYASA..71..727B. PMID 13583829. doi:10.1111/j.1749-6632.1958.tb46803.x.
↑  Bishop PM. . Gardiner-Hill H  (编).  1. London: Butterworth & Co. 1958: 231–244.
↑  Bishop PM. . Thomas. 1962: 78.
↑  .   [2024-02-04]. （原始内容存档于2018-09-17）.
↑  Sweetman SC (编). .  36th. London: Pharmaceutical Press. 2009: 2098. ISBN 978-0-85369-840-1.